A Study of ATL1102 or Placebo in Participants With Non-ambulatory Duchenne Muscular Dystrophy

NCT05938023 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
48
Enrollment
INDUSTRY
Sponsor class

Stopped The study failed to meet its primary or secondary efficacy endpoints. In consultation with investigators, the sponsor determined that it is not in the best interests of patients for the study to continue.

Conditions

Interventions

Sponsor

Percheron Therapeutics